Skip to content
Screener

Halozyme Therapeutics HALO Q1 2026 earnings

Reported May 11, 2026 · After market close

Revenue$376.7MBeat by $18.1M
EPS$1.60Beat by $0.06
Revenue estimate$358.6M
EPS estimate$1.54

Next report

Nov 2, 2026 (in a month)
Revenue estimate$482.3M
EPS estimate$2.25

Financials

Q1 2026

Income statement

See full
Revenue$376.7M+42.2%
Gross profit$297.5M+37.4%
Operating income$184.5M+30.4%
Net income$150.0M+27.1%
EPS (diluted)$1.22+31.2%

Balance sheet

See full
Cash & equivalents$312.0M+76.9%
Total debt$2.2B+41.7%
Total equity$219.6M-54.5%
Total assets$2.7B+21.7%

Cash flow

See full
Operating cash flow$180.1M+16.8%
CapEx$3.7M+294%
Free cash flow$176.3M+15.0%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$7.66B-2.9%
Enterprise value$9.52B+3.0%
P/S5.1×-2.2×

Profitability

See full
Gross margin82.8%-0.7pp
FCF margin44.3%-1.5pp

Returns & leverage

See full
Debt / equity9.9×+6.7×
Current ratio2.8×-5.6×

Segments

By product

See full
Royalties$240.7M+43.1%
Bulk rHuPH20 sales$73.5M+172%
Proprietary product sales$41.9M+15.2%
Device partnered product sales$15.1M+2.6%
Device licensing and development revenue$5.6M+64.4%

FAQ

When did Halozyme Therapeutics report Q1 2026 earnings?
Halozyme Therapeutics (HALO) reported Q1 2026 earnings on May 11, 2026 after market close.
What were Halozyme Therapeutics's Q1 2026 revenue and EPS?
Halozyme Therapeutics reported revenue of $376.7M and eps of $1.60 for Q1 2026.
Did Halozyme Therapeutics beat estimates in Q1 2026?
Revenue beat the consensus estimate of $358.6M by $18.1M. EPS beat the consensus estimate of $1.54 by $0.06.
How did Halozyme Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 42.2% from $264.9M a year earlier and eps grew 44.1% from $1.11.
Where can I find Halozyme Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001159036-26-000067) and the 10-Q periodic report (0001159036-26-000068) directly on SEC EDGAR. The filing index links above go to sec.gov.